Results 91 to 100 of about 230,556 (169)

Impact of Graves' orbitopathy on quality of life

, 2014
Objective. This study was conducted to assess the impact of Graves' orbitopathy on the quality of life in our population by using disease-specific questionnaire (GO-QOL) recommended by the European Group on Graves' Orbitopathy (EUGOGO). Methods.
Bubanja D., Ćirić J., Bubanja I., Sulubiric D.   +3 more
core   +1 more source

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' Orbitopathy

, 2016
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease.
Bartalena, Luigi, Eckstein, Anja, Kahaly, George J., Salvi, Mario, Marcocci, Claudio, On behalf of the European Group on Graves'' Orbitopathy (EUGOGO), Dayan, Colin Mark, Perros, Petros, European Group on Graves' Orbitopathy (EUGOGO), Baldeschi, Lelio, Boboridis, Kostas, Wiersinga, Wilmar M   +11 more
core   +1 more source

The endonasale orbital decompression in the management of Graves´ orbitopathy

, 2011
Die endonasal mirkoskopisch-endoskopische Orbitadekompression stellt eine sichere und effiziente Therapieform in der Behandlung der endokrinen Orbitopathie dar.Orbitadecompression is a safe method in the management of Graves ...
Rauch, Sabine
core   +1 more source

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Archives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova, Kiril Hristozov, Aleksandra Tsukeva   +2 more
doaj   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Graves’ orbitopathy: the importance of statin therapy [PDF]

Background. Graves’ orbitopathy is the most common extrathyroidal autoimmune disorder, predominantly caused by hyperthyroidism. Prevention and development of an individualized treatment plan involve the use of statins and the management of risk factors:
Rizov, Cristina, Tidvă, Adelina
core  

What\u27s New in Graves\u27 Orbitopathy?

, 2018
Graves\u27 orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves\u27 disease (GD). Depending upon the diagnostic criteria used up to 50% of patients with GD have ophthalmic findings; with lid retraction/lid lag being the most ...
Jim Garrity, MD
core   +1 more source

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

Clinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica   +5 more
doaj   +1 more source

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question

, 2017
There is a general belief that Graves' orbitopathy (GO) is a "chronic" disease, namely that patients' eyes do not return to how they were before GO appeared.
Elena Sabini, Rocchi, Roberto, Michele Marinò, Paolo Vitti, Mazzi, Barbara, Sabini, Elena, Latrofa, Francesco, Leo, Marenza, Barbara Mazzi, Vitti, Paolo, Marenza Leo, Claudio Marcocci, Marcocci, Claudio, Nardi, Marco, Marinò, Michele, Marco Nardi, Francesco Latrofa, Roberto Rocchi   +17 more
core   +1 more source

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

Frontiers in Immunology
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact.
Alan Chun Hong Lee, George J. Kahaly
doaj   +1 more source